RVP

Business Context and Reporting Period

Company: Retractable Technologies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2007
Business Overview: The Company designs, develops, manufactures, and markets safety syringes (primarily the VanishPoint® syringe) and other safety medical products. Operations are based in Little Elm, Texas, with significant manufacturing capacity outsourced to Double Dove in China (80.6% of units produced in Q1 2007). The Company faces market access challenges due to monopolistic practices by competitors, specifically Becton Dickinson & Co. (BD), though it continues to pursue international markets and federal contracts (e.g., PATH).

Key Financial Metrics

Liquidity: Cash represents 64.3% of total assets. The Company utilized approximately $1.2 million in cash for operating activities, with additional cash used for capital expenditures ($224,212) and debt repayments ($95,355).

Material Changes vs. Prior Period

• Revenue Composition: While total sales increased slightly, the mix shifted significantly. Domestic revenues decreased 18.3% due to lower pricing, while international revenues surged 224.7% driven by shipments to African countries under the PATH program. Overall unit sales increased 61.5%.
• Profitability: Gross profit declined by 34.1% despite higher unit volumes. This was caused by lower average selling prices associated with the high volume of international sales and domestic price reductions. Operating expenses increased 26.9%, driven by higher sales/marketing compensation and legal fees.
• Cost Structure: The average cost of manufactured product sold per unit decreased by 22.2%, attributed to increased production volumes and the use of Chinese manufacturing (Double Dove).
• Reimbursed Discounts: The Company received no reimbursed discounts in Q1 2007, compared to $1.64 million in Q1 2006. The discount reimbursement program from the BD settlement concluded on December 31, 2006.

Outlook, Risks, and Contingencies

• Market Access: Management states that profitability depends on gaining better access to hospital markets, which remains difficult due to competitor monopolistic practices. If cash from operations becomes insufficient, the Company plans to implement cost-cutting measures, including workforce reductions and deferral of royalty payments to founder Thomas Shaw.
• Supply Chain Risk: Approximately 80.6% of production is outsourced to Double Dove in China. Disruption in this supply chain would require finding an alternative supplier to avoid production halts.
• Litigation: The Company is engaged in ongoing litigation against Abbott Laboratories regarding marketing fees and against BD regarding antitrust practices. A lawsuit against Abbott will proceed in court rather than arbitration.
• Licensing: The Company expects royalty streams from a license agreement with BTMD in China in 2007, pending government approvals. No royalties have been received to date, but the Company does not plan to terminate the agreement.
• Dividends: Significant dividends are in arrears for Series I through V Class B Convertible Preferred Stock. A payment of $1,060,000 is scheduled for July 24, 2007, for Series I and II holders.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $45.3 million cash reserve given the $2.3 million net loss and $1.2 million operating cash outflow in a single quarter.
• International Dependency: Assess the risk concentration in international sales (PATH program) which drove volume but compressed margins.
• Preferred Stock Arrears: Confirm the total liability for preferred dividends in arrears (totaling over $12 million across all series) and the impact on common equity.
• Supply Chain Resilience: Evaluate the contingency plan if the primary Chinese manufacturer (Double Dove) fails to deliver.
• Litigation Outcomes: Monitor the status of the Abbott lawsuit and any potential impact on future marketing capabilities or financial settlements.